Posted by Michael Wonder on 03 Dec 2025
Ionis receives US FDA breakthrough therapy designation for zilganersen for Alexander disease
2 December 2025 - On track to submit new drug application in Q1, 2026.
Ionis Pharmaceuticals today announced that the US FDA has granted breakthrough therapy designation to zilganersen for the treatment of Alexander disease, a rare, progressive and often fatal neurological condition.
